“I expect those 5 products to kind of have maybe not 100%, but pretty high growth rate in next -- in this year.”

In context

“or investment. Robert Funck: We'll take one more question. Operator: And our last question will come from Matt Miksic from Barclays. Matthew Miksic: I figure maybe just if we can wrap it up with an update on a couple of the pipeline products, the 5 products, Robert, that you've highlighted in the past, Amulet and CardioMEMS, maybe if you could just talk a little bit about where you are with these launches in terms of size, scale, momentum and maybe what kinds of catalysts we can look for or metrics we can see for these 2 products this year? Robert Ford: Sure. I mean I think those 5 products that I discussed on the last call, and we talked about them exiting at an annual run rate of [ 500 ]. They actually exited at a run rate of [ 550 ] and they grew around -- they grew around 100%. So I expect those 5 products to kind of have maybe not 100%, but pretty high growth rate in next -- in this year. Regarding Amulet, listen, I think it's -- like I said, it's a great space. We've been rolling out the product last year, building the sales force. Key focus here is obviously ensuring good implanting technique with the physicians. We're in about 225 accounts right now. I expect that in terms of growth catalysts, getting more share of those existing accounts as the physicians become more and more accustomed to using our product and see the benefits of using our product versus other systems I think that will be a growth catalyst and then expanding. We do want to start to expand more. As our sales force has increased, the competency of our sales team has increased and our clinical team has increased, we feel more confident now to be able to kind of expand more accounts. And that's what we'”